

# Biomarker analysis report

2017-08-29

## Contents

<b>1</b>	<b>The dataset</b>	<b>1</b>
<b>2</b>	<b>Representativeness: Selection Bias of Biomarker Population</b>	<b>1</b>
2.1	Check selection bias in terms of key clinical variables, between full population and BEP . . .	2
2.2	Check whether the clinical outcome in BEP is comparable to the full population . . . . .	2
2.3	Examine whether the prognostic/predictive/null trend of key clinical variables holds in BEP .	3
2.4	Compare treatment effect estimation in full population and in BEP, adjusted for key clinical variables . . . . .	5
<b>3</b>	<b>Biomarker property and its association to clinical variables</b>	<b>6</b>
3.1	Biomarker property and relationship to clinical variable . . . . .	6
3.2	Whether the biomarker shows within-arm effect . . . . .	6
<b>4</b>	<b>Biomarker cutoff exploration/selection</b>	<b>8</b>
4.1	Try different cutoffs - look for consistent trend . . . . .	8
4.2	Estimations within non-overlapping bins . . . . .	9
4.3	Estimations within overlapped sliding windows - STEPP plot . . . . .	10
<b>5</b>	<b>Biomarker subgroup analysis (using selected cutoff)</b>	<b>11</b>
5.1	Estimations within each subgroup . . . . .	11
5.2	KM curves . . . . .	12
5.3	Check whether biomarker subgroup is confounded with key clinical variables . . . . .	13

## 1 The dataset

The dataset have 550 entries. In which 461 are in biomarker evaluable population (BEP).

- Endpoint of interest: PFS
- Biomarker: KRAS.exprs
- Biomarker type: numeric

## 2 Representativeness: Selection Bias of Biomarker Population

In this section, we are trying to answer the question: *Are biomarker evaluable population representative of the full population population?*

Key baseline demographics and prognostic characteristics (including stratification variables and any variables with known prognostic effect) and efficacy outcomes should be summarized by treatment groups and compared between biomarker evaluable population (BEP) and the full population. These analyses are conducted to investigate any potential selection bias associated with the availability of the biomarker (e.g. we may not get enough tissue for patients whose tumor size is small. Therefore they may be excluded from BEP).

The key clinical biomarkers considered are:

```
clinical.vars.class
```

```
##           Sex           Age
## "categorical"      "numeric"
```

## 2.1 Check selection bias in terms of key clinical variables, between full population and BEP


```
kable(SummaryVars(data=input, trt=trt, subgroup=BEP, subgroup.indicator = BEP.indicator, var=clinical.v
```

	All(CTRL)	BEP(CTRL)	All(TRT)	BEP(TRT)
Sex				
Total	182	152	368	309
NA's	0	0	0	0
F	89 (48.9%)	73 (48.03%)	184 (50%)	147 (47.57%)
M	93 (51.1%)	79 (51.97%)	184 (50%)	162 (52.43%)
Age				
N	182	152	368	309
Mean	52.54	52.35	54.03	54.29
Median	51.5	51	54	54
Min-Max	27...85	27...85	30...89	30...89
NA's	0	0	0	0

## 2.2 Check whether the clinical outcome in BEP is comparable to the full population

The following plot compares survival outcome in BEP vs. the full population. The KM curve and 95% CI are plotted for each arm. The BEP KM curve is expected to be within the full population confidence bands.

```
CompareKM(data=input, tte=outcome.var[1], cen=outcome.var[2], trt=trt, bep=BEP, bep.indicator = BEP.indicator)
```




## 2.3 Examine whether the prognostic/predictive/null trend of key clinical variables holds in BEP

The following forest plot can be used to examine whether any of the key prognostic/predictive clinical variables still show prognostic/predictive trend in BEP:

```
forest.bep <- PlotTabForestMulti(data=input,
                                outcome.class=outcome.class,
                                outcome.var=outcome.var,
                                trt=trt,
                                var=clinical.vars,
                                var.class=clinical.vars.class,
                                bep=BEP,bep.indicator=BEP.indicator,
                                compare.bep.itt=TRUE
                                )
```

```
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
```

**Across arm, Compare BEP vs. All  
PFS  
Unadjusted, unstratified analysis**



## 2.4 Compare treatment effect estimation in full population and in BEP, adjusted for key clinical variables

The following analyses show summary statistic to look at the trt/ctrl (target/reference) HR in full population and trt/ctrl HR in BEP. Both unadjusted and adjusted analyses are performed

```
kable(
  CoxTab(data=input, tte=outcome.var[1], cens=outcome.var[2], var=trt,
    var.class="categorical"),
  caption="full population, unadjusted"
)
```

Table 2: full population, unadjusted

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Arm (TRT/CTRL)	0.54	0.43	0.67	7.8e-08	368	182

```
kable(
  CoxTab(data=input, tte=outcome.var[1], cens=outcome.var[2], var=c(trt, clinical.vars), var.class=c("categorical", "continuous"),
  caption="full population, adjusted for clinical variables"
)
```

Table 3: full population, adjusted for clinical variables

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Arm (TRT/CTRL)	0.53	0.42	0.66	4.1e-08	368	182
Sex (M/F)	0.9	0.72	1.12	0.36	277	273
Age	1.01	1	1.02	0.079		

```
kable(
  CoxTab(data=input.bep, tte=outcome.var[1], cens=outcome.var[2], var=trt,
    var.class="categorical"),
  caption="BEP, unadjusted"
)
```

Table 4: BEP, unadjusted

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Arm (TRT/CTRL)	0.56	0.43	0.71	3.5e-06	309	152

```
kable(
  CoxTab(data=input.bep, tte=outcome.var[1], cens=outcome.var[2], var=c(trt, clinical.vars), var.class=c("categorical", "continuous"),
  caption="BEP, adjusted for clinical variables"
)
```

Table 5: BEP, adjusted for clinical variables

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Arm (TRT/CTRL)	0.55	0.43	0.7	2.1e-06	309	152
Sex (M/F)	0.93	0.73	1.18	0.53	241	220

	HR	CI.low	CI.high	p-value	n.trt	n.ref
Age	1.01	1	1.02	0.052		

If any selection bias is suspected, you may consider to stratify for the imbalanced factor in downstream analysis (e.g. unstratified analysis as primary analysis and stratified analysis as sensitivity analysis).

### 3 Biomarker property and its association to clinical variables


Before performing cutoff exploratory analysis, it is important to check a biomarker's property. For example, whether this biomarker has a bi-modal or multi modal distribution - if so, this biomarker may have natural cutoff.

Relationship between the biomarker and key demographic and prognostic variables should also be investigated using bivariate plots. Prognostic property of the biomarker should also be assessed, by estimates of the clinical efficacy in the control arm.

#### 3.1 Biomarker property and relationship to clinical variable

The following results show single variate plot for biomarker and bi-variate plots to investigate biomarker-clinical variable relationship.

```
PlotProperty(data=input, biomarker.var=bm, biomarker.class=bm.class,
             var=clinical.vars,
             var.class=clinical.vars.class,
             log2=FALSE, par.param = list(mfrow=c(2,3)))
```



#### 3.2 Whether the biomarker shows within-arm effect


The following figures investigate whether the biomarker shows a within-arm effect (e.g. patients with higher biomarker value tend to have better clinical outcome):

```
input.ctrl <- subset(input, Arm==placebo.code) ## Data with only ctrl samples
res.multicut.ctrl <- PlotTabForestBiomarker(data=input.ctrl,
                                           outcome.class=outcome.class,
                                           outcome.var=outcome.var,
                                           var=bm,
                                           var.class=bm.class,
                                           percentile.cutoff=percentile.trycut,
```

```
numerical.cutoff = numerical.trycut,
main.prefix=placebo.code,
greater=TRUE, less=FALSE,
covariate=covariate, strata=strata)
```

```
## Some patients have missing outcome. Exclude these patients from ITT.
## Some NAs in var column, will define the non NA entries as BEP
## only 1 arm; show.itt is set to FALSE
## only 1 arm; show.bep is set to FALSE
```


**CTRL Within-arm Effect of Biomarker**  
**PFS, KRAS.exprs**  
**Unadjusted, unstratified analysis**



```
input.trt <- subset(input, Arm==active.code) ## Data with only ctrl samples
res.multicut.trt <- PlotTabForestBiomarker(data=input.trt,
outcome.class=outcome.class,
outcome.var=outcome.var,
var=bm,
var.class=bm.class,
percentile.cutoff=percentile.trycut,
numerical.cutoff = numerical.trycut,
main.prefix=active.code,
greater=TRUE, less=FALSE,
covariate=covariate, strata=strata)
```

```
## Some patients have missing outcome. Exclude these patients from ITT.
## Some NAs in var column, will define the non NA entries as BEP
## only 1 arm; show.itt is set to FALSE
## only 1 arm; show.bep is set to FALSE
## Warning in par(old.par): calling par(new=TRUE) with no plot
```

**TRT Within-arm Effect of Biomarker**  
**PFS, KRAS.exprs**  
**Unadjusted, unstratified analysis**



The forest plots above show within-arm HR of biomarker high ( $\geq$  cutoff) vs. low ( $<$  cutoff) group. For a given arm, if the HR is not all around 1, it indicates that within this arm the biomarker has an association to the clinical outcome. For example, within treatment arm, suppose all high vs. low HR are less than 1 and the HR is smaller when cutting at a higher value. This indicates that among patients who received treatment, patients who have higher biomarker value tends to have better clinical outcome .

If similar trend is seen in both arms, it indicates that the biomarker may have a prognostic effect (the biomarker is able to identify patients with better/worse clinical outcome, regardless of treatment).

## 4 Biomarker cutoff exploration/selection

Results in this section could be used to examine multiple candidate cutoffs for a continuous biomarker. The need for cut-off determination should be rooted in the development strategy. In general, an exhaustive search looking at all possible cut-off values is not recommended for decision making. Over-optimized cutoff using one set of clinical data may lead to hard-to-reproduce results. When determining a cutoff, biomarker property should be considered - e.g. cut at a low-dense point may be more robust to population shift. The cutoff selection should also fit the program's stratigitic considerations. There is always a prevalence-effect size trade-off, inputs from multiple functions are needed - for example whether the team is willing to take more risk in PTS (high prevalence, weaker signal) or the team is willing to target at smaller population (lower prevalence, stronger signal)

### 4.1 Try different cutoffs - look for consistent trend

The following plots investigate whether the biomarker is predictive across arm. To perform cross-arm analysis. TRT/CTRL HR within biomarker high or low group are calculated. The high/low groups are defined by trying different cutoffs.

```
res.multicut <- PlotTabForestBiomarker(data=input,
                                       outcome.class=outcome.class,
                                       outcome.var=outcome.var,
                                       trt=trt,
                                       var=bm,
                                       var.class=bm.class,
                                       percentile.cutoff=percentile.trycut,
                                       numerical.cutoff = numerical.trycut,
```




```
greater=TRUE, less=TRUE,
show.itt=TRUE, show.bep=TRUE,
covariate=covariate, strata=strata)
```

```
## Some patients have missing outcome. Exclude these patients from ITT.
```

```
## Some NAs in var column, will define the non NA entries as BEP
```

**Across-arm Effect of Biomarker**  
**PFS, KRAS.exprs**  
**Unadjusted, unstratified analysis**



## 4.2 Estimations within non-overlapping bins


The following figure show TRT/CTRL HR within non-overlapping bins defined by those exploratory cutoffs.

```
res.multicut <- PlotTabForestBiomarker(data=input,
outcome.class=outcome.class,
outcome.var=outcome.var,
trt=trt,
var=var,
var.class=var.class,
percentile.cutoff=percentile.trycut,
numerical.cutoff = numerical.trycut,
greater=FALSE, less=FALSE, within.bin=TRUE,
show.itt=TRUE, show.bep=TRUE,
covariate=covariate, strata=strata)
```

```
## Some patients have missing outcome. Exclude these patients from ITT.
```

```
## Some NAs in var column, will define the non NA entries as BEP
```

**Across-arm Effect of Biomarker**  
**PFS, KRAS.exprs**  
**Unadjusted, unstratified analysis**



### 4.3 Estimations within overlapped sliding windows - STEPP plot


STEPP refers to Subgroup Treatment Effect Pattern Plot and it investigates relationship between biomarker and treatment effect. Only continuous biomarkers are suitable for STEPP analysis. STEPP performs treatment effect estimation on overlapping subsets of patients defined according to the biomarker level. The default setting of run.STEPP slides subgroup windows by 5% for each step and the subgroup size is 25% of the whole population.

A monotone trend is expected to be seen for an ideal biomarker.

```
stepp.out <- PlotSTEPP(data = input,
                        outcome.class=outcome.class,
                        outcome.var=outcome.var,
                        trt=trt,
                        var=bm,
                        placebo.code = placebo.code,
                        active.code = active.code
)
```

## some NA in var column, will ignore NA entries

## STEPP: Subgroup Treatment Effect Pattern Plot



## 5 Biomarker subgroup analysis (using selected cutoff)

### 5.1 Estimations within each subgroup

The following figure shows estimate of treatment effect in biomarker subgroups, defined by the selected cutoff.

```
if(bm.class=="numeric"){
  if(!is.null(numerical.finalcut)) levs <- paste0(c(">=", "<"), numerical.finalcut)
  if(is.null(numerical.finalcut)) {
    nm <- quantile(input.bep[[bm]], percentile.finalcut, 2) # default quantile type in forest plot function
    numerical.finalcut <- round(nm, 2) # default rounding decimal in forest plots
    levs <- paste0(c(">=", "<"), percentile.finalcut*100, "%")
  }

  bm2 <- paste0(bm, "_Dx")
  input[[bm2]] <- ifelse(input[[bm]] >= numerical.finalcut, levs[1], levs[2])
  input[[bm2]] <- factor(input[[bm2]], levels=levs) # ">=" as Dx+
}

if(bm.class=="categorical") {
  bm2 <- bm
  levs <- unique(input[[bm2]])
}

res.2group <- PlotTabForestBiomarker(data=input,
                                     outcome.class=outcome.class,
```

```


outcome.var=outcome.var,
trt=trt,
var=bm2,
var.class="categorical",
greater=TRUE, less=TRUE,
show.itt=TRUE, show.bep=TRUE,
covariate=covariate, strata=strata)

```

## Some patients have missing outcome. Exclude these patients from ITT.

## Some NAs in var column, will define the non NA entries as BEP

**Across-arm Effect of Biomarker**  
**PFS, KRAS.exprs\_Dx**  
**Unadjusted, unstratified analysis**




## 5.2 KM curves

The following figure show KM curves of the biomarker subgroups, based on selected cutoff:

```

km.out <- PlotKM(data=input, tte=outcome.var[1], cen=outcome.var[2], bep=BEP,
  trt=trt, var=bm2, var.class="categorical",
  legend.loc="topright",
  plot.median=FALSE)

```



CTRL, $\geq 50\%$	70	44	23	9	4	2	0	0
CTRL, $< 50\%$	82	58	31	15	9	4	1	0
TRT, $\geq 50\%$	162	145	105	47	30	12	5	0
TRT, $< 50\%$	147	113	83	38	20	6	2	0

### 5.3 Check whether biomarker subgroup is confounded with key clinical variables

The following table checks whether the biomarker subgroup is confounded with clinical variables. Here we check whether the clinical variable distribution is comparable in biomarker high and low group.

```
input.bep <- input[which(input[[BEP]]==BEP.indicator),]
```

```
kable(
  SummaryVars(data=input.bep, trt=trt, subgroup=bm2, var=clinical.vars,
    var.class=clinical.vars.class, subgroup.indicator=levs[1], compare.subgroup=TRUE)
)
```

	KRAS.exprs_Dx_ $\geq 50\%$ (CTRL)	KRAS.exprs_Dx_ $< 50\%$ (CTRL)	KRAS.exprs_Dx_ $\geq 50\%$ (TRT)	KRAS.exprs_Dx_ $< 50\%$ (TRT)
Sex				
Total	70	82	162	147
NA's	0	0	0	0
F	35 (50%)	38 (46.34%)	77 (47.53%)	70 (47.62%)
M	35 (50%)	44 (53.66%)	85 (52.47%)	77 (52.38%)
Age				
N	70	82	162	147

	KRAS.exprs_Dx_>=50%(CTRL)	KRAS.exprs_Dx_<50%(CTRL)	KRAS.exprs_Dx_>=50%(TRT)	KRAS.exprs_Dx_<50%(TRT)
Mean	51.5	53.07	53.36	55.31
Median	50	52	53	55
Min-Max	27...85	35...82	33...89	30...82
NA's	0	0	0	0

The following plot show treatment effect estimations in smaller subgroups defined by both biomarker and clinical variables. For numerical clinical variable, it is dichotomized by its median.

```
res.subgroup.cov <- PlotTabForestMulti(data=input,
                                       outcome.class=outcome.class,
                                       outcome.var=outcome.var,
                                       trt=trt,
                                       var=clinical.vars,
                                       var.class=clinical.vars.class,
                                       compare.bep.itt=FALSE,
                                       compare.subgroup=TRUE,
                                       subgroup=bm2,
                                       covariate=covariate, strata=strata
                                       )
```

```
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
## Some patients have missing outcome. Exclude these patients from ITT.
```

#### Across arm, Compare KRAS.exprs\_Dx subgroup

##### PFS

##### Unadjusted, unstratified analysis

